The Association of Clinicopathological Features with Metastatic Status in Infiltrative Urothelial Carcinoma of Bladder
Background: Infiltrative urothelial carcinoma of bladder is an aggressive variant of bladder carcinoma. Most of the patients in their first encounter with doctors are diagnosed with advanced stages and many has metastasized. Metastasis is a process of malignant tumor cells migrating from its primary tumor location to other organs or sites inside the body via blood circulation or lymphatic system. Metastasis process is responsible for 90% cancer deaths compared to the primary tumor itself, infiltrative urothelial carcinoma of bladder. To reduce mortality, knowledge of the clinicopathological characteristics associated with metastasis is needed.
Method: Research material used was clinical data and paraffin block from patients with metastatic and non-metastatic infiltrative urothelial carcinoma of bladder. Clinical data taken from Central Medical Record Installation and Urology Medical Record Installation Padjadjaran University/ Dr. Hasan Sadikin Hospital Bandung, Indonesia. Paraffin blocks were obtained from operations at Hasan Sadikin Hospital Bandung, Indonesia.Total data sample obtained were 40 samples, 20 samples are metastatic and another 20 are non-metastatic samples. Clinicopathological parameters included in the analysis were age, sex and pathalogical T stage.
Result: Pathalogical T stage have associations with metastatic status with significant result with p value=0.035 (p<0.005).
Conclusion: Pathalogical T stage was associated with the metastatic status of Infiltrative urothelial carcinoma of bladder and may play important roles during the metastatic process. Thus, it can be used as a predictor factor for the infiltrative urothelial carcinoma of bladder.
Keywords: infiltrative urothelial carcinoma of bladder, metastastic, pathalogical T stage
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018 Nov; 68(6):394-424.
3. Fred T. Bosman MP ESJM, Sunil R.Lakhani MF, Hiroko Ohgaki. P.Tumours of the urinary tract. In: Holger Moch PAH, Thomas M.U I bright, Victor E.Reuter (Eds), editor. WHO Classification of Tumours of the Urinary System and Male Genital Organs.4 ed.Lyon, France: International Agency for Research on Cancer (IARC) Press: International Agency for Research on Cancer (IARC) Press; 2016.hlm.77-106. 2016; 77-106.
4. Cheng L, Lopez-Beltran A, Bostwick DG. Bladder Pathology: John Wiley & Sons; 2012.
5. Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. International journal of urology : official journal of the Japanese Urological Association. 2017 Oct; 24(10):730-4.
6. Arvelo F, Sojo F, Cotte C. Tumour progression and metastasis. Ecancermedicalscience. 2016; 10:617.
7. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduction and Targeted Therapy. 2020 2020/03/12; 5(1):28.
8. Otsuka M, Taguchi S, Nakagawa T, Morikawa T, Maekawa S, Miyakawa J, et al. Clinical significance of random bladder biopsy in primary T1 bladder cancer. Mol Clin Oncol. 2018 2018/05/01; 8(5):665-70.
9. Amin MB, Epstein JI, Reuter VE. Biopsy interpretation of the bladder. Philadelphia, PA: Wolters Kluwer; 2017.
10. Matulay JT KA. Epidemiology and Etiology of Bladder Cancer. Uro Today. 2019.
11. Li Y, Chen M, Yuan J, Zhou X, He W, Zu X, et al. CXCR4 Expression in Bladder Transitional Cell Carcinoma and Its Relationship with Clinicopathological Features. Urologia Internationalis. 2014; 92(2):157-63.
12. Kim SH, Song MK, Joung JY, Chung J, Lee KH, Seo HK. Significant clinicopathologic prognostic factors for bladder recurrence, progression, and cancer-specific survival after surgery among patients with upper urinary tract urothelial carcinoma. Investigative and clinical urology. 2019 Nov; 60(6):432-42.
13. Reis ST, Leite KRM, Piovesan LF, Pontes-Junior J, Viana NI, Abe DK, et al. Increased expression of MMP-9 and IL-8 are correlated with poor prognosis of Bladder Cancer. BMC Urology. 2012 2012/06/13; 12(1):18.
14. Retz MM, Sidhu SS, Blaveri E, Kerr SC, Dolganov GM, Lehmann J, et al. CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. 2004.
15. Li J, Guo BC, Sun LR, Wang JW, Fu XH, Zhang SZ, et al. TNM staging of colorectal cancer should be reconsidered by T stage weighting. World journal of gastroenterology. 2014 May 7; 20(17):5104-12.
16. Yousef EM, Tahir MR, St-Pierre Y, Gaboury LA. MMP-9 expression varies according to molecular subtypes of breast cancer. BMC cancer. 2014 Aug 23; 14:609.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).